Xencor, Inc.

Symbol: XNCR

NASDAQ

23.54

USD

Market price today

  • -11.4370

    P/E Ratio

  • -0.8496

    PEG Ratio

  • 1.45B

    MRK Cap

  • 0.00%

    DIV Yield

Xencor, Inc. (XNCR) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.93%

Operating Profit Margin

-0.82%

Net Profit Margin

-0.74%

Return on Assets

-0.13%

Return on Equity

-0.19%

Return on Capital Employed

-0.16%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Bassil I. Dahiyat Ph.D.
Full-time employees:280
City:Monrovia
Address:111 West Lemon Avenue
IPO:2013-12-03
CIK:0001326732

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

General Outlook

When we look at how much money they make before expenses, they keep 0.932% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.815%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.744%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.131% return, is a testament to Xencor, Inc.'s adeptness in optimizing resource deployment. Xencor, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.186%. Furthermore, the proficiency of Xencor, Inc. in capital utilization is underscored by a remarkable -0.158% return on capital employed.

Stock Prices

Xencor, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $24.42, while its low point bottomed out at $20.85. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Xencor, Inc.'s stock market.

Liquidity Ratios

Analyzing XNCR liquidity ratios reveals its financial health of the firm. The current ratio of 735.65% gauges short-term asset coverage for liabilities. The quick ratio (714.23%) assesses immediate liquidity, while the cash ratio (63.50%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio735.65%
Quick Ratio714.23%
Cash Ratio63.50%

Profitability Ratios

XNCR profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -71.55% underscores its earnings before tax deductions. The effective tax rate stands at 0.88%, revealing its tax efficiency. The net income per EBT, 103.99%, and the EBT per EBIT, 87.75%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -81.54%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-71.55%
Effective Tax Rate0.88%
Net Income per EBT103.99%
EBT per EBIT87.75%
EBIT per Revenue-81.54%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 7.36, it details the span from stock purchase to revenue. The 7 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 1491.04% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding714
Operating Cycle24.48
Days of Payables Outstanding442
Cash Conversion Cycle-417
Receivables Turnover14.91
Payables Turnover0.83
Fixed Asset Turnover1.68
Asset Turnover0.18

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 1.40, and free cash flow per share, 1.05, depict cash generation on a per-share basis. The cash per share value, 9.76, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.51, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share1.40
Free Cash Flow per Share1.05
Cash per Share9.76
Operating Cash Flow Sales Ratio0.51
Free Cash Flow to Operating Cash Flow Ratio0.75
Cash Flow Coverage Ratio3.49
Short Term Coverage Ratio8.71
Capital Expenditure Coverage Ratio4.01
Dividend Paid and Capex Coverage Ratio4.01

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 2.56%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.04, we discern the balance between debt and equity financing. The long-term debt to capitalization, 2.14%, and total debt to capitalization, 3.52%, ratios shed light on its capital structure. An interest coverage of 162.05 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio2.56%
Debt Equity Ratio0.04
Long Term Debt to Capitalization2.14%
Total Debt to Capitalization3.52%
Interest Coverage162.05
Cash Flow to Debt Ratio3.49
Company Equity Multiplier1.42

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 2.78, provides a glimpse into top-line earnings distributed across each share. Net income per share, -2.08, reflects the portion of profit attributed to each share. The book value per share, 11.05, represents the net asset value distributed per share, while the tangible book value per share, 10.75, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share2.78
Net Income Per Share-2.08
Book Value Per Share11.05
Tangible Book Value Per Share10.75
Shareholders Equity Per Share11.05
Interest Debt Per Share0.40
Capex Per Share-0.35

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 2.28%, indicates top-line expansion, while the gross profit growth, 0.68%, reveals profitability trends. EBIT growth, -68.10%, and operating income growth, -68.10%, offer insights into operational profitability progression. The net income growth, -128.50%, showcases bottom-line expansion, and the EPS growth, -123.66%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth2.28%
Gross Profit Growth0.68%
EBIT Growth-68.10%
Operating Income Growth-68.10%
Net Income Growth-128.50%
EPS Growth-123.66%
EPS Diluted Growth-123.66%
Weighted Average Shares Growth1.43%
Weighted Average Shares Diluted Growth1.43%
Operating Cash Flow Growth247.60%
Free Cash Flow Growth437.54%
10-Year Revenue Growth per Share757.62%
5-Year Revenue Growth per Share268.30%
3-Year Revenue Growth per Share29.74%
10-Year Operating CF Growth per Share908.86%
5-Year Operating CF Growth per Share194.80%
3-Year Operating CF Growth per Share1708.36%
10-Year Net Income Growth per Share-8.44%
5-Year Net Income Growth per Share-59.08%
3-Year Net Income Growth per Share-87.65%
10-Year Shareholders Equity Growth per Share371.33%
5-Year Shareholders Equity Growth per Share13.89%
3-Year Shareholders Equity Growth per Share10.48%
Receivables Growth-61.06%
Inventory Growth-1129000100.00%
Asset Growth12.58%
Book Value per Share Growth-9.36%
Debt Growth39.91%
R&D Expense Growth27.08%
SGA Expenses Growth-11.81%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 1,314,128,698.09, captures the company's total value, considering both debt and equity. Income quality, -0.68, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.32, gauges operational efficiency, while the research and development to revenue, 150.65%, highlights investment in innovation. The ratio of intangibles to total assets, 1.96%, indicates the value of non-physical assets, and capex to operating cash flow, -24.97%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value1,314,128,698.09
Income Quality-0.68
Sales General and Administrative to Revenue0.32
Research and Development to Revenue150.65%
Intangibles to Total Assets1.96%
Capex to Operating Cash Flow-24.97%
Capex to Revenue-12.62%
Capex to Depreciation-184.82%
Stock-Based Compensation to Revenue31.93%
Graham Number22.77
Return on Tangible Assets-13.50%
Graham Net Net5.17
Working Capital538,451,000
Tangible Asset Value650,470,000
Net Current Asset Value339,601,000
Average Receivables20,143,500
Average Payables12,001,000
Average Inventory-5,644,999.5
Days Sales Outstanding24
Days Payables Outstanding442
Days of Inventory On Hand-358
ROIC-20.96%
ROE-0.19%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 2.14, and the price to book ratio, 2.14, reflect the market's valuation relative to the company's book value. The price to sales ratio, 8.62, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 22.72, and price to operating cash flows, 16.83, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio2.14
Price to Book Ratio2.14
Price to Sales Ratio8.62
Price Cash Flow Ratio16.83
Price Earnings to Growth Ratio-0.85
Enterprise Value Multiple-10.61
Price Fair Value2.14
Price to Operating Cash Flow Ratio16.83
Price to Free Cash Flows Ratio22.72
Price to Tangible Book Ratio1.92
Enterprise Value to Sales7.81
Enterprise Value Over EBITDA-10.34
EV to Operating Cash Flow15.44
Earnings Yield-9.82%
Free Cash Flow Yield4.97%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Xencor, Inc. (XNCR) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -11.437 in 2024.

What is the ticker symbol of Xencor, Inc. stock?

The ticker symbol of Xencor, Inc. stock is XNCR.

What is company IPO date?

IPO date of Xencor, Inc. is 2013-12-03.

What is company current share price?

Current share price is 23.540 USD.

What is stock market cap today?

The market cap of stock today is 1451182150.000.

What is PEG ratio in 2024?

The current -0.850 is -0.850 in 2024.

What is the number of employees in 2024?

In 2024 the company has 280.